{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:53:15Z","timestamp":1786981995825,"version":"build-2736575974"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T00:00:00Z","timestamp":1701302400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T00:00:00Z","timestamp":1701302400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Osteoporos"],"DOI":"10.1007\/s11657-023-01358-z","type":"journal-article","created":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T21:01:33Z","timestamp":1701291693000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Budget impact of increasing uptake of denosumab for the treatment of postmenopausal osteoporosis in Malaysia"],"prefix":"10.1007","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6393-0617","authenticated-orcid":false,"given":"Yai Wen","family":"Choo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0353-4799","authenticated-orcid":false,"given":"Nurul Ain","family":"Mohd Tahir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1459-1844","authenticated-orcid":false,"given":"Mohd Shahrir","family":"Mohamed Said","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0592-0645","authenticated-orcid":false,"given":"Mohd","family":"Makmor Bakry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3329-3095","authenticated-orcid":false,"given":"Shu Chuen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,30]]},"reference":[{"key":"1358_CR1","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1007\/s11657-020-00871-9","volume":"16","author":"JA Kanis","year":"2021","unstructured":"Kanis JA, Norton N, Harvey NC et al (2021) SCOPE 2021: a new scorecard for osteoporosis in Europe. Arch Osteoporos 16:82. https:\/\/doi.org\/10.1007\/s11657-020-00871-9","journal-title":"Arch Osteoporos"},{"key":"1358_CR2","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.afos.2018.03.003","volume":"4","author":"C-L Cheung","year":"2018","unstructured":"Cheung C-L, Ang SB, Chadha M et al (2018) An updated hip fracture projection in Asia: the Asian Federation of Osteoporosis Societies study. Osteoporos Sarcopenia 4:16\u201321. https:\/\/doi.org\/10.1016\/j.afos.2018.03.003","journal-title":"Osteoporos Sarcopenia"},{"key":"1358_CR3","unstructured":"Pharmaceutical Services Programme (2021) Official Portal of Pharmaceutical Services Programme, Ministry of Health Malaysia. https:\/\/www.pharmacy.gov.my\/v2\/en. Accessed 21 Apr 2021"},{"key":"1358_CR4","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1210\/jc.2019-00192","volume":"104","author":"P Barrionuevo","year":"2019","unstructured":"Barrionuevo P, Kapoor E, Asi N et al (2019) Efficacy of pharmacological therapies for the prevention of fractures in postmenopausal women: a network meta-analysis. Journal of Clinical Endocrinology and Metabolism 104:1623\u20131630. https:\/\/doi.org\/10.1210\/jc.2019-00192","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"1358_CR5","volume-title":"Malaysian Statistics on Medicines, 2015-2016","author":"Pharmaceutical Services Programme","year":"2020","unstructured":"Pharmaceutical Services Programme (2020) Malaysian Statistics on Medicines, 2015-2016. Ministry of Health Malaysia, Malaysia"},{"key":"1358_CR6","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1007\/s00198-022-06444-5","volume":"33","author":"YW Choo","year":"2022","unstructured":"Choo YW, Mohd Tahir NA, Mohamed Said MS et al (2022) Cost-effectiveness of denosumab for the treatment of postmenopausal osteoporosis in Malaysia. Osteoporosis International 33:1909\u20131923. https:\/\/doi.org\/10.1007\/s00198-022-06444-5","journal-title":"Osteoporosis International"},{"key":"1358_CR7","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1007\/s00198-021-06268-9","volume":"33","author":"Y Wan","year":"2022","unstructured":"Wan Y, Zeng F, Tan H et al (2022) Cost-effectiveness analyses of denosumab for osteoporosis: a systematic review. Osteoporosis International 33:979\u20131015. https:\/\/doi.org\/10.1007\/s00198-021-06268-9","journal-title":"Osteoporosis International"},{"key":"1358_CR8","doi-asserted-by":"publisher","unstructured":"Li N, Cornelissen D, Silverman S et al (2020) An updated systematic review of cost-effectiveness analyses of drugs for osteoporosis. Pharmacoeconomics. https:\/\/doi.org\/10.1007\/s40273-020-00965-9","DOI":"10.1007\/s40273-020-00965-9"},{"key":"1358_CR9","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.jval.2013.08.2291","volume":"17","author":"SD Sullivan","year":"2014","unstructured":"Sullivan SD, Mauskopf JA, Augustovski F et al (2014) Budget impact analysis - principles of good practice: Report of the ISPOR 2012 budget impact analysis good practice II task force. Value in Health 17:5\u201314. https:\/\/doi.org\/10.1016\/j.jval.2013.08.2291","journal-title":"Value in Health"},{"key":"1358_CR10","volume-title":"Pharmacoeconomic Guidelines for Malaysia","author":"Ministry of Health Malaysia","year":"2019","unstructured":"Ministry of Health Malaysia (2019) Pharmacoeconomic Guidelines for Malaysia, 2nd edn. Ministry of Health Malaysia, Malaysia","edition":"2"},{"key":"1358_CR11","unstructured":"World Bank Group (2021) GDP deflator (base year varies by country) - Malaysia. https:\/\/data.worldbank.org\/indicator\/NY.GDP.DEFL.ZS?end=2019&locations=MY&start=2010. Accessed 15 Feb 2021"},{"key":"1358_CR12","unstructured":"Central Bank of Malaysia (2021) Exchange Rates 2019. https:\/\/www.bnm.gov.my\/exchange-rates. Accessed 1 Mar 2021"},{"key":"1358_CR13","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-50482-7","volume-title":"Budget-impact analysis of health care interventions: a practical guide","author":"J Mauskopf","year":"2017","unstructured":"Mauskopf J, Earnshaw SR, Brogan A et al (2017) Budget-impact analysis of health care interventions: a practical guide. Springer International Publishing, Switzerland"},{"key":"1358_CR14","doi-asserted-by":"publisher","unstructured":"Chan CY, Subramaniam S, Mohamed N et al (2020) Determinants of bone health status in a multi-ethnic population in Klang Valley, Malaysia. Int J Environ Res Public Health 17. https:\/\/doi.org\/10.3390\/ijerph17020384","DOI":"10.3390\/ijerph17020384"},{"key":"1358_CR15","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.afos.2017.05.001","volume":"3","author":"SS Yeap","year":"2017","unstructured":"Yeap SS, Nur Fazirah MFR, Nur Aisyah C et al (2017) Trends in post osteoporotic hip fracture care from 2010 to 2014 in a private hospital in Malaysia. Osteoporos Sarcopenia 3:112\u2013116. https:\/\/doi.org\/10.1016\/j.afos.2017.05.001","journal-title":"Osteoporos Sarcopenia"},{"key":"1358_CR16","unstructured":"Department of Statistics Malaysia (2021) Current Population Estimates, Malaysia, 2021, Malaysia"},{"key":"1358_CR17","volume-title":"Malaysian Statistics on Medicines, 2011-2014","author":"Pharmaceutical Services Programme","year":"2017","unstructured":"Pharmaceutical Services Programme (2017) Malaysian Statistics on Medicines, 2011-2014. Ministry of Health Malaysia, Malaysia"},{"key":"1358_CR18","first-page":"e129","volume":"5","author":"A Parthan","year":"2013","unstructured":"Parthan A, Emptage NP, Taylor DCA et al (2013) Budgetary impact analysis of denosumab in a US health plan. American Journal of Pharmacy Benefits 5:e129\u2013e138","journal-title":"American Journal of Pharmacy Benefits"},{"key":"1358_CR19","first-page":"605","volume":"14","author":"ANA Tosteson","year":"2008","unstructured":"Tosteson ANA, Burge RT, Marshall DA, Lindsay R (2008) Therapies for treatment of osteoporosis in US women: cost-effectiveness and budget impact considerations. American Journal of Managed Care 14:605\u2013615","journal-title":"American Journal of Managed Care"},{"key":"1358_CR20","doi-asserted-by":"publisher","first-page":"e11470","DOI":"10.1097\/MD.0000000000011470","volume":"97","author":"H Cho","year":"2018","unstructured":"Cho H, Byun JH, Song I et al (2018) Effect of improved medication adherence on health care costs in osteoporosis patients. Medicine (United States) 97:e11470. https:\/\/doi.org\/10.1097\/MD.0000000000011470","journal-title":"Medicine (United States)"},{"key":"1358_CR21","doi-asserted-by":"publisher","unstructured":"Mangano GRA, Avola M, Blatti C et al (2023) Non-adherence to anti-osteoporosis medication: factors influencing and strategies to overcome it. A narrative review. J Clin Med 12. https:\/\/doi.org\/10.3390\/jcm12010014","DOI":"10.3390\/jcm12010014"},{"key":"1358_CR22","unstructured":"Centre HI (2021) Health Facts 2021: Reference Data for 2020, Malaysia"},{"key":"1358_CR23","volume-title":"Malaysian DRG Executive Information System","author":"Medical Development Division","year":"2021","unstructured":"Medical Development Division (2021) Malaysian DRG Executive Information System. Ministry of Health Malaysia http:\/\/casemix-eis.moh.gov.my\/. Accessed 1 Feb 2021"},{"key":"1358_CR24","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.semarthrit.2019.01.006","volume":"49","author":"M Hiligsmann","year":"2019","unstructured":"Hiligsmann M, Williams SA, Fitzpatrick LA et al (2019) Cost-effectiveness of sequential treatment with abaloparatide vs. teriparatide for United States women at increased risk of fracture. Semin Arthritis Rheum 49:184\u2013196. https:\/\/doi.org\/10.1016\/j.semarthrit.2019.01.006","journal-title":"Semin Arthritis Rheum"},{"key":"1358_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1478-7547-12-8","volume":"12","author":"K Thorlund","year":"2014","unstructured":"Thorlund K, Zafari Z, Druyts E et al (2014) The impact of incorporating Bayesian network meta-analysis in cost-effectiveness analysis - a case study of pharmacotherapies for moderate to severe COPD. Cost Effectiveness and Resource Allocation 12:1\u20139. https:\/\/doi.org\/10.1186\/1478-7547-12-8","journal-title":"Cost Effectiveness and Resource Allocation"}],"container-title":["Archives of Osteoporosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11657-023-01358-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11657-023-01358-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11657-023-01358-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T08:41:50Z","timestamp":1704357710000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11657-023-01358-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,30]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1358"],"URL":"https:\/\/doi.org\/10.1007\/s11657-023-01358-z","relation":{},"ISSN":["1862-3514"],"issn-type":[{"value":"1862-3514","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,30]]},"assertion":[{"value":"7 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}],"article-number":"145"}}